MA31895B1 - (alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates - Google Patents

(alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates

Info

Publication number
MA31895B1
MA31895B1 MA32880A MA32880A MA31895B1 MA 31895 B1 MA31895 B1 MA 31895B1 MA 32880 A MA32880 A MA 32880A MA 32880 A MA32880 A MA 32880A MA 31895 B1 MA31895 B1 MA 31895B1
Authority
MA
Morocco
Prior art keywords
diseases
treatment
compounds
alkyl
branched
Prior art date
Application number
MA32880A
Other languages
English (en)
Inventor
Sven Weiler
Leo Widler
Jean-Michel Rondeau
Simona Cotesta
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31895(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31895B1 publication Critical patent/MA31895B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR DES ACIDES [(IMIDAZOL-1-YL)-1-HYDROXY-1-PHOSPHONOÉTHYL] PHOSPHONIQUES SUBSTITUÉS PAR ALKYLE EN C2-C5, AINSI QUE SUR DES MÉTHODES OU DES PROCÉDÉS PERMETTANT DE LES FABRIQUER, SUR LEUR UTILISATION DANS LA FABRICATION DE FORMULATIONS PHARMACEUTIQUES, SUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES, SUR DES PROCÉDÉS D'UTILISATION DE CEUX-CI DANS LE TRAITEMENT DE MALADIES, SUR DES FORMULATIONS PHARMACEUTIQUES LES ENGLOBANT ET/OU SUR LES COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES. LES COMPOSÉS SONT CAPABLES D'INHIBER UNE RÉSORPTION OSSEUSE EXCESSIVE OU INAPPROPRIÉE ET SONT APPROPRIÉS POUR LE TRAITEMENT D'AUTRES MALADIES QUI SONT PROVOQUÉES PAR UNE PRÉNYLATION EXCESSIVE DE PROTÉINES CIBLES, TELLES QUE LE SYNDROME DE PROGÉRIE D'HUTCHINSON-GILFORD. LES COMPOSÉS SONT REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE L'UN PARMI R1 ET R2 REPRÉSENTE HYDROGÈNE ET L'AUTRE REPRÉSENTE ALKYLE EN C2-C5 QUI EST RAMIFIÉ OU NON RAMIFIÉ, ET PEUVENT SE PRÉSENTER SOUS UNE FORME LIBRE, SOUS LA FORME D'UN ESTER ET/OU D'UN SEL.
MA32880A 2007-11-30 2010-05-31 (alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates MA31895B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122016 2007-11-30

Publications (1)

Publication Number Publication Date
MA31895B1 true MA31895B1 (fr) 2010-12-01

Family

ID=39154111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32880A MA31895B1 (fr) 2007-11-30 2010-05-31 (alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates

Country Status (24)

Country Link
US (2) US7977323B2 (fr)
EP (1) EP2225252B1 (fr)
JP (1) JP5244917B2 (fr)
KR (1) KR20100092035A (fr)
CN (1) CN101835787A (fr)
AR (1) AR069437A1 (fr)
AU (1) AU2008328797B2 (fr)
BR (1) BRPI0819902A2 (fr)
CA (1) CA2701516A1 (fr)
CL (1) CL2008003545A1 (fr)
CO (1) CO6280421A2 (fr)
CR (1) CR11362A (fr)
EA (1) EA201000860A1 (fr)
EC (1) ECSP10010321A (fr)
ES (1) ES2386851T3 (fr)
IL (1) IL204657A0 (fr)
MA (1) MA31895B1 (fr)
MX (1) MX2010005786A (fr)
NZ (1) NZ584219A (fr)
PE (1) PE20091038A1 (fr)
TN (1) TN2010000138A1 (fr)
TW (1) TW200932248A (fr)
WO (1) WO2009068567A1 (fr)
ZA (1) ZA201001992B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001578A1 (ru) * 2008-04-04 2011-06-30 Новартис Аг Фармацевтическая композиция с бисфосфонатом
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
EP2576576A4 (fr) 2010-05-28 2014-03-05 Univ Mcgill Acide hétérocyclyle-pyridinyle bisphosphonique, sel pharmaceutiquement acceptable de celui-ci, composition en contenant et son procédé d'utilisation
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2019076269A1 (fr) 2017-10-16 2019-04-25 清华大学 Inhibiteur de la voie de l'acide mévalonique et composition pharmaceutique correspondante
CN112980809B (zh) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199052I1 (de) 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
SK90093A3 (en) * 1991-02-26 1994-09-07 Norwich Eaton Pharma Mixture of phosphonite and estrogene for treatment of osteoporosis
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
EP1802641B8 (fr) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Composes de bisphosphonate et methodes de traitement de maladies de resorption osseuse, de cancers, de douleurs osseuses, de troubles immunitaires et de maladies infectieuses
AR063121A1 (es) 2006-10-05 2008-12-30 Novartis Ag Composicion farmaceutica
CN101679422A (zh) 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物

Also Published As

Publication number Publication date
US7977323B2 (en) 2011-07-12
JP5244917B2 (ja) 2013-07-24
ZA201001992B (en) 2010-12-29
TN2010000138A1 (en) 2011-09-26
EP2225252A1 (fr) 2010-09-08
EP2225252B1 (fr) 2012-06-27
ES2386851T3 (es) 2012-09-03
US20110224173A1 (en) 2011-09-15
IL204657A0 (en) 2010-11-30
WO2009068567A1 (fr) 2009-06-04
BRPI0819902A2 (pt) 2015-05-19
ECSP10010321A (es) 2010-08-31
CR11362A (es) 2010-06-14
JP2011504908A (ja) 2011-02-17
EA201000860A1 (ru) 2010-12-30
CA2701516A1 (fr) 2009-06-04
KR20100092035A (ko) 2010-08-19
CN101835787A (zh) 2010-09-15
MX2010005786A (es) 2010-06-09
CO6280421A2 (es) 2011-05-20
NZ584219A (en) 2012-03-30
PE20091038A1 (es) 2009-08-19
TW200932248A (en) 2009-08-01
AR069437A1 (es) 2010-01-20
CL2008003545A1 (es) 2009-06-05
AU2008328797B2 (en) 2011-11-03
US20090143337A1 (en) 2009-06-04
AU2008328797A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
Weyermann et al. A practical note on the use of cytotoxicity assays
KR102255778B1 (ko) 질환의 치료를 위한 ｋｄｍ１ａ 저해인자
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA31766B1 (fr) Composés organiques
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
WO2014164867A1 (fr) Inhibiteurs de kdm1a pour le traitement d&#39;une maladie
TNSN00202A1 (fr) Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant
MA33083B1 (fr) Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament
MA29909B1 (fr) Derives de pyridazine
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31504B1 (fr) Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes
CY1111808T1 (el) Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d&#39;inhibiteurs de proteine-kinases
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu&#39;inhibiteurs de kinase jak
EP1887007A3 (fr) Imidazo- et thiazolopyridines en tant qu&#39;inhibiteurs de la JAK3 kinase
CN110809467A (zh) Sestrin-gator2相互作用的调节剂及其用途
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d&#39;alzheimer
CN102131775B (zh) 雄激素受体n-末端活化的小分子抑制剂
MA29554B1 (fr) Nouveaux derives d&#39;amide d&#39;acide piperidine carboxylique
MA45803A1 (fr) Pyrido [3,4-b] indoles substitués pour le traitement de troubles du cartilage
EP3630759A1 (fr) Composés inhibiteurs des canaux ioniques pour le traitement du cancer
Hou et al. Cardioprotective effect of taurine and β-alanine against cardiac disease in myocardial ischemia and reperfusion-induced rats